Novo Nordisk is looking past the needle. The company behind Ozempic is now leaning on pill versions to drive its next stretch of growth, and a new Wegovy pill launch in Germany has already helped steady its stock. Elsewhere today, the FDA cleared Mounjaro for cutting cardiovascular risk in adults with type 2 diabetes, and hundreds of thousands of Medicare patients are now paying just $50 a month for GLP-1 drugs. A member of Congress even found a new political use for Ozempic's name.
Novo Nordisk, the company that built its recent success on Ozempic, is now looking past its blockbuster injectable to secure its next chapter of growth. According to a New York Times report, oral versions of its GLP-1 drugs may be the company's answer as competition intensifies and current products mature. Moving from injections to pills could make treatment easier for patients who prefer not to use needles, and it could open the drug to people who have avoided treatment for that reason. This shift in strategy comes as the company faces increasing competitive pressure, both from other companies and from new formulations of its own drugs.
Access is also improving on the cost side for a large group of patients. A new Medicare program now allows hundreds of thousands of patients to pay just $50 a month for GLP-1 drugs, a sharp drop from out-of-pocket costs that could previously exceed $1,000 a month. This change removes one of the biggest barriers that has kept eligible patients from starting or continuing treatment. For many older adults managing diabetes or related conditions, this pricing shift could mean the difference between consistent treatment and going without it.
As more patients gain access to these drugs, the FDA is also expanding what they are approved to treat. On August 28, the agency approved Mounjaro (tirzepatide) for reducing cardiovascular risk in adults with type 2 diabetes, adding to its existing approvals for blood sugar control and weight management. This approval gives doctors another reason to consider Mounjaro for patients who face heart related complications alongside diabetes. It also reflects a broader trend in the GLP-1 category, where drugs originally developed for one purpose are proving useful for several related health outcomes.
That broader trend is playing out directly in Novo Nordisk's stock performance. The company's shares steadied after the launch of a Wegovy pill in Germany, a milestone that highlighted just how much the obesity treatment market continues to grow. Investors have been watching closely for signs that Novo Nordisk can keep pace with competitors, and this launch offered some reassurance. The stock reaction shows how closely tied Novo Nordisk's financial outlook is to its ability to expand into new formulations and new markets.
Not all of today's attention on these drugs is about medicine or markets. Rep. Andy Ogles publicly blamed Ozempic for country singer Jelly Roll's recent comments about former President Trump, a claim that has drawn attention mostly for how it reflects public perception of the drug rather than any medical basis. The comment illustrates how Ozempic has become a shorthand reference in political and cultural commentary, often disconnected from its actual clinical use. It also shows how a drug developed for diabetes and weight management has become a recognizable name well beyond the health care conversation.
Across these stories, GLP-1 drugs are expanding in nearly every direction at once: in the forms they take, the costs patients pay, the conditions they treat, and the public conversations they generate. If you are a patient, it may be worth checking whether new pricing programs or expanded approvals apply to your treatment plan. For readers simply following the news, remember that this category is moving quickly, so it helps to separate real clinical developments from commentary that treats these drugs as a cultural symbol rather than a medical treatment.
Key details
Novo Nordisk, the company behind Ozempic, may turn to pill versions for future growth.
Hundreds of thousands of Medicare patients now pay just $50 for GLP-1 drugs monthly.
The FDA approved Mounjaro to cut cardiovascular risk for adults with type 2 diabetes.
Wegovy's pill launch in Germany helped steady Novo Nordisk's stock amid obesity growth.
Rep. Andy Ogles blamed Ozempic for country singer Jelly Roll's comments about Trump.
Read this on GLP-1 Nation: https://glp1nation.com/edition/35
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.